AA
AlphaCentric Advisors Portfolio holdings
AUM
$100M
This Quarter Return
+7.09%
1 Year Return
+18.84%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$166M
AUM Growth
+$166M
(+11%)
Cap. Flow
+$18.9M
Cap. Flow
% of AUM
11.41%
Top 10 Holdings %
Top 10 Hldgs %
22.19%
Holding
254
New
38
Increased
43
Reduced
118
Closed
26
Top Buys
| 1 |
United Therapeutics
UTHR
|
$3.68M |
| 2 |
NARI
Inari Medical, Inc. Common Stock
NARI
|
$2.78M |
| 3 |
Pfizer
PFE
|
$2.64M |
| 4 |
Axsome Therapeutics
AXSM
|
$2.59M |
| 5 |
Corcept Therapeutics
CORT
|
$2.14M |
Top Sells
| 1 |
IMGN
Immunogen Inc
IMGN
|
$3.78M |
| 2 |
WBA
Walgreens Boots Alliance
WBA
|
$3.13M |
| 3 |
ABVX
Abivax
ABVX
|
$2.86M |
| 4 |
Ironwood Pharmaceuticals
IRWD
|
$2.8M |
| 5 |
Amylyx Pharmaceuticals
AMLX
|
$2.22M |
Sector Composition
| 1 | Healthcare | 61.45% |
| 2 | Real Estate | 11.2% |
| 3 | Financials | 4.6% |
| 4 | Industrials | 3.92% |
| 5 | Technology | 2.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Pfizer
PFE
$141B
| $4.86M | 2.93% |
175,000
+95,000
| +119% | +$2.64M |
|
2
Rithm Capital
RITM
$6.57B
| $4.7M | 2.83% |
420,966
+20,000
| +5% | +$223K |
|
3
Harmony Biosciences
HRMY
$2.12B
| $4.1M | 2.47% |
122,000
| – | – |
|
|
4
United Therapeutics
UTHR
$13.8B
| $3.68M | 2.22% |
+16,000
| New | +$3.68M |
|
5
Pacira BioSciences
PCRX
$1.2B
| $3.43M | 2.07% |
117,500
| – | – |
|
6
BioCryst Pharmaceuticals
BCRX
$1.74B
| $3.43M | 2.07% |
675,000
| – | – |
|
7
Galapagos
GLPG
$2.07B
| $3.38M | 2.04% |
105,000
| – | – |
|
8
argenx
ARGX
$43.6B
| $3.15M | 1.9% |
8,000
+250
| +3% | +$98.4K |
|
|
NARI
9
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $3.02M | 1.82% |
63,000
+58,000
| +1,160% | +$2.78M |
|
10
DocGo
DCGO
$153M
| $2.63M | 1.58% |
650,000
+340,000
| +110% | +$1.37M |
|
|
ONC
11
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $2.62M | 1.58% |
16,750
+9,250
| +123% | +$1.45M |
|
|
EFC
12
Ellington Financial
EFC
$1.36B
| $2.62M | 1.58% |
221,602
| – | – |
|
|
13
Axsome Therapeutics
AXSM
$6.05B
| $2.59M | 1.56% |
+32,500
| New | +$2.59M |
|
14
MGIC Investment
MTG
$6.42B
| $2.56M | 1.54% |
114,379
+35,000
| +44% | +$783K |
|
15
uniQure
QURE
$896M
| $2.39M | 1.44% |
460,000
+38,975
| +9% | +$203K |
|
16
Coherus Oncology, Inc. Common Stock
CHRS
$135M
| $2.39M | 1.44% |
1,000,000
| – | – |
|
17
Mirum Pharmaceuticals
MIRM
$3.71B
| $2.36M | 1.42% |
94,000
+44,000
| +88% | +$1.11M |
|
|
DX
18
Dynex Capital
DX
$1.64B
| $2.26M | 1.36% |
181,492
| – | – |
|
19
UroGen Pharma
URGN
$900M
| $2.16M | 1.3% |
143,898
-11,102
| -7% | -$167K |
|
|
20
Corcept Therapeutics
CORT
$7.35B
| $2.14M | 1.29% |
+85,000
| New | +$2.14M |
|
21
Perspective Therapeutics
CATX
$250M
| $2.09M | 1.26% |
+1,756,756
| New | +$2.09M |
|
22
Amicus Therapeutics
FOLD
$2.34B
| $2.06M | 1.24% |
175,000
+35,000
| +25% | +$412K |
|
23
Exact Sciences
EXAS
$8.98B
| $2M | 1.21% |
+29,000
| New | +$2M |
|
|
MFA
24
MFA Financial
MFA
$1.05B
| $1.91M | 1.15% |
167,725
+25,000
| +18% | +$285K |
|
|
RWT
25
Redwood Trust
RWT
$791M
| $1.84M | 1.11% |
288,343
+141,750
| +97% | +$903K |
|